Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05367440 · ClinicalTrials.gov registry record · Phase 1

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
174
Enrollment target
20
Study locations

NCT05367440 is a Phase 1 study of Metastatic Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 174 participants, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05367440, a Phase 1 study of Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
174 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG Darolutamide
  • DRUG Apalutamide
  • DRUG Enzalutamide
  • DRUG Abiraterone Acetate
  • DRUG AZD5305

Study Locations (20)

Other

  • Research Site - Camperdown
  • Research Site - Darlinghurst
  • Research Site - East Melbourne
  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - St Leonards
  • Research Site - Candiolo
  • Research Site - Milan
  • Research Site - Orbassano
  • Research Site - Padua
  • Research Site - Cambridge
  • Research Site - Glasgow
  • Research Site - Manchester
  • Research Site - Plymouth

Michigan

  • Research Site - Detroit
  • Research Site - Detroit

Texas

  • Research Site - Houston
  • Research Site - Houston

New York

  • Research Site - Syracuse

South Carolina

  • Research Site - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2022-06-02
Est. Completion 2031-04-11
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05367440

The ClinicalTrials.gov registry entry for NCT05367440 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Darolutamide is the first listed.

NCT05367440 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT05367440 about?

NCT05367440 is a clinical study titled "Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer". This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

What is the current status of trial NCT05367440?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2022-06-02. Estimated completion is 2031-04-11.

What conditions does trial NCT05367440 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT05367440?

The interventions under investigation include: Darolutamide (DRUG), Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), AZD5305 (DRUG).

Who is sponsoring clinical trial NCT05367440?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05367440 being conducted?

This trial has 20 study locations across Michigan, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.